GLP-1 Constipation: How Common It Is by Drug, How to Get Relief, and When to Worry
Published:
GLP-1 constipation is common, miserable, and usually manageable — but “drink more water” isn't enough when you haven't pooped in five days, your belly feels tight, and you're standing in the laxative aisle wondering if any of it is safe to take with the shot you gave yourself yesterday. Here's the part you came for.
The 60-second answer
GLP-1 constipation is one of the most common side effects of these medications. Per current FDA prescribing information on DailyMed, constipation is reported in roughly 24% of adults on Wegovy 2.4 mg, 20% on Wegovy 7.2 mg, 19% on Saxenda 3 mg, 11–17% on Zepbound, 6–7% on Mounjaro, 5–6% on Rybelsus, and 3–5% on Ozempic.
For most people, hydration, gradual fiber, walking after meals, and a gentle osmotic laxative is enough. Call your prescriber if you've gone 5+ days without a bowel movement, if a dose increase keeps triggering this, or if it's getting worse. Go to the ER for severe or worsening belly pain, persistent vomiting, a hard distended belly, no gas passing, fever with belly pain, blood or black/tarry stool, fainting, or confusion.
Wegovy 2.4 mg
24%
constipation
Saxenda 3 mg
19%
constipation
Zepbound
11–17%
constipation
Mounjaro
6–7%
constipation
Rybelsus
5–6%
constipation
Ozempic
3–5%
constipation
Victoza 1.8 mg
5%
constipation
Trulicity 1.5 mg
3.7%
constipation
Source: current FDA prescribing information on DailyMed. See full table and notes below.
GLP-1 Constipation Rates by Drug
Every percentage below comes from the current FDA prescribing information on DailyMed — the official US drug-label database run by the National Library of Medicine. We pulled the drug's constipation rate, the placebo rate from the same trial, and the absolute difference — the part you can actually credit to the medication.
| Medication (active) | Indication & dose | Drug rate | Placebo rate | Absolute excess | ~1 extra per |
|---|---|---|---|---|---|
| Wegovy (semaglutide) | Weight mgmt, 2.4 mg | 24% | 11% | +13% | ~8 patients |
| Wegovy (semaglutide) | Weight mgmt, 7.2 mg | 20% | 8% | +12% | ~8 patients |
| Saxenda (liraglutide) | Weight mgmt, 3 mg | 19.4% | 8.5% | +10.9% | ~9 patients |
| Zepbound (tirzepatide) | Weight mgmt, 5 mg | 17% | 5% | +12% | ~8 patients |
| Zepbound (tirzepatide) | Weight mgmt, 10 mg | 14% | 5% | +9% | ~11 patients |
| Zepbound (tirzepatide) | Weight mgmt, 15 mg | 11% | 5% | +6% | ~17 patients |
| Mounjaro (tirzepatide) | Type 2 diabetes, 5 mg | 6% | 1% | +5% | ~20 patients |
| Mounjaro (tirzepatide) | Type 2 diabetes, 10 mg | 6% | 1% | +5% | ~20 patients |
| Mounjaro (tirzepatide) | Type 2 diabetes, 15 mg | 7% | 1% | +6% | ~17 patients |
| Rybelsus (oral semaglutide) | Type 2 diabetes, 7 mg | 6% | 2% | +4% | ~25 patients |
| Rybelsus (oral semaglutide) | Type 2 diabetes, 14 mg | 5% | 2% | +3% | ~33 patients |
| Ozempic (semaglutide) | Type 2 diabetes, 0.5 mg | 5.0% | 1.5% | +3.5% | ~29 patients |
| Ozempic (semaglutide) | Type 2 diabetes, 1 mg | 3.1% | 1.5% | +1.6% | ~63 patients |
| Victoza (liraglutide) | Type 2 diabetes, 1.2 1.8 mg | 5% | 1% | +4% | ~25 patients |
| Trulicity (dulaglutide) | Type 2 diabetes, 0.75 mg | 3.9% | 0.7% | +3.2% | ~31 patients |
| Trulicity (dulaglutide) | Type 2 diabetes, 1.5 mg | 3.7% | 0.7% | +3.0% | ~33 patients |
Sources: Current FDA prescribing information for each drug on DailyMed (linked in sources section below). “Absolute excess” = drug rate − placebo rate. “~1 extra report per” = 1 ÷ absolute excess, rounded — editorial math, not a formal number-needed-to-harm.
Not a head-to-head ranking. Every percentage came from a separate trial with different patients, different lengths, and different definitions. DailyMed labels explicitly note that adverse-reaction rates from different trials cannot be directly compared. Read it as “here's what the FDA approved each drug knowing about” — not as a ranking of which drug is worst for everyone.
Why GLP-1s Cause Constipation in the First Place
Quick answer: GLP-1 medications slow how fast food leaves your stomach (gastric emptying) and slow how fast stool moves through your colon. Slower transit means more water gets pulled out of stool, leaving it harder, drier, and more difficult to pass. Eating less and drinking less — both common on these drugs — make it worse.
The drug class works by copying a gut hormone called GLP-1 (glucagon-like peptide-1), which your body releases when you eat. Real GLP-1 tells your pancreas to release insulin, tells your brain you're full, and tells your stomach to slow down so food sticks around longer. The medication versions do all three, on purpose, harder and longer.
That third effect — the slowdown — is what helps you feel full on smaller meals. It's also the same effect that backs you up. A 2025 retrospective single-center case series in ACG Case Reports Journal used a wireless motility capsule in 10 patients on GLP-1 receptor agonists already being worked up for constipation or gastroparesis: 80% had delayed gastric emptying and 44% had delayed whole-gut transit. Small group, mechanism support — not a population-level rate.
Three things that stack on top of that
- 1You’re eating less. Less food in means less stool to push out. That alone reduces how often you go.
- 2You’re drinking less. Fullness and nausea make people drink less, and the 2022 multidisciplinary expert consensus on GLP-1 GI side effects specifically points to reduced water intake as one reason constipation can drag on.
- 3Dose increases re-trigger it. Each step up in dose is essentially a new “starting” event for your gut. Side effects often flare for one to three weeks before the body adapts to the new level.
This is why a generic “drink water and eat fiber” answer falls short. It's right, but it's not enough — and the timing matters more than most pages tell you.
Going Less vs Actually Being Constipated — They're Not the Same Thing
Quick answer: Going to the bathroom less often is not the same as being constipated. If your stool is still soft, you can pass gas, and you don't feel painfully backed up, you're probably just eating less. Constipation is hard, dry, lumpy stool, straining, painful bowel movements, bloating, or a feeling that something is stuck.
Mayo Clinic defines constipation by symptoms, not by frequency alone — fewer than three bowel movements per week, hard or lumpy stools, straining, painful bowel movements, a sense that you can't fully empty, or feeling blocked. Going every other day with soft, easy stool and no pain is not constipation. It's a slower system handling less food.
| Probably just going less | Probably actually constipated |
|---|---|
| ✓ Stool is soft when you go | ⚠ Stool is hard, dry, or lumpy (“rabbit pellets”) |
| ✓ No straining | ⚠ Straining or painful bowel movements |
| ✓ Can pass gas normally | ⚠ Can’t pass gas, or passing gas is painful |
| ✓ No belly pain | ⚠ Belly pain, cramping, or feeling blocked |
| ✓ You feel okay | ⚠ Bloated, uncomfortable, or like something is stuck |
| ✓ Eating noticeably less | ⚠ Doesn’t matter how much you ate |
If you're in the left column, you may not need to do anything except keep an eye on it. If you're in the right column, the rest of this page is for you.
How Long Does GLP-1 Constipation Last?
Quick answer: GLP-1 constipation is most often reported early — onset typically in the first 16 weeks, especially the first 28 days, and symptoms persisted a median of about 47 days in people with obesity on GLP-1 therapy (2022 multidisciplinary expert consensus). Each dose increase can bring symptoms back, so track timing instead of assuming one fixed flare length.
| Stage | When | What's typical | What helps |
|---|---|---|---|
| 1. Starting out | Weeks 1–4, lowest dose | Mild slowdown common. Often manageable with hydration and walking alone. | Build the prevention habit early — fluids, fiber-friendly meals, daily movement. |
| 2. First dose increase | Weeks 4–8 | Symptoms often flare for 1–3 weeks after each step up. | Add psyllium fiber gradually. Keep PEG (MiraLAX) on standby. |
| 3. Adaptation window | Weeks 8–16 | Constipation is most likely to peak in this window per the consensus paper. | Stick with the routine. Talk to your prescriber if it’s disrupting your life. |
| 4. Steady state | Weeks 16+ | GI side effects diminish for many people. | Some stay on a maintenance fiber or PEG dose long-term. Persistent severe symptoms past this point should trigger a prescriber review. |
What to Do Right Now — a Stepped Relief Plan
Quick answer: Don't pile on laxatives. Start with steady fluids, gradual fiber if you tolerate it, walking after meals, and a predictable bathroom routine. If you use an OTC laxative, follow the product label and check with your pharmacist or prescriber first — especially if you have kidney disease, IBS, abdominal pain, vomiting, pregnancy, dehydration risk, or take prescription medications. Stop and seek same-day medical care for severe or worsening belly pain, persistent vomiting, inability to pass gas, a hard distended belly, fever, blood in stool, fainting, or confusion — any day, regardless of how long it's been.
| Day since last BM | What to try | Escalate if… |
|---|---|---|
| Day 1 (no severe symptoms) | Track it. Drink fluids steadily through the day, walk 10–15 minutes after meals, use a footstool on the toilet, don’t ignore the urge. | Severe pain, vomiting, hard swollen belly, no gas, fever, or blood/black stool — any day. |
| Day 2–3, hard stool or bloating | Keep fluids and walking. Add psyllium husk fiber gradually with extra water (start small — one teaspoon). Consider polyethylene glycol (PEG 3350, MiraLAX) per the product label — adult labeled dose is 17 g once daily in 4–8 oz of water. The MiraLAX label says not to use longer than 7 days unless a doctor tells you to. | Worsening bloating, pain, vomiting, or inability to pass gas. |
| Day 3–5, still backed up | Don’t stack three new products. If PEG isn’t enough after a few days, ask your pharmacist whether a stool softener (docusate / Colace) or a magnesium-based osmotic laxative fits your situation per its label. Skip magnesium-based options if you have kidney disease, are an older adult, or take heart-rhythm medications, unless your prescriber has cleared it. | Symptoms getting worse, dehydration, significant pain, or no gas. |
| Day 5–7, home steps not working | Call your prescriber. Ask whether to hold the next dose escalation, adjust the bowel plan, or use a short-term rescue option. Stimulant laxatives (senna, bisacodyl / Dulcolax) work in 6–12 hours but are intended for short-term rescue, not daily use. | Severe pain, persistent vomiting, hard distended belly, no gas, fever, or blood/black stool. |
| Day 7+ or red flags any day | Don’t keep experimenting at home. Get same-day medical advice; use urgent care or the ER for red flags. | ER for severe pain, persistent vomiting, no gas, hard distended belly, fainting, confusion, or severe dehydration. |
A few things this plan deliberately does NOT do:
- Don’t stack laxatives at random. Senna + magnesium + MiraLAX + a stool softener at the same time is a recipe for cramping, electrolyte issues, and dependency.
- Don’t dump a huge load of fiber on a backed-up gut. Add gradually, with extra water, after the worst has eased.
- Don’t change your GLP-1 dose on your own. Talk to your prescriber first.
- Don’t rely on enemas. A one-time enema can be a useful rescue under guidance, but repeated use is not a sustainable plan.
Fluid needs change with kidney disease, heart disease, vomiting, diarrhea, activity, climate, and body size — there isn't a universal number that's right for everyone.
The Best Laxatives for GLP-1 Constipation (and What to Skip)
Quick answer: Among OTC options, polyethylene glycol (PEG 3350, MiraLAX) has the strongest guideline support for adult constipation. It's an osmotic laxative — it pulls water into the colon to soften stool — and the FDA GLP-1 labels we checked don't list it as a direct interaction. Psyllium fiber works for prevention. Stimulant laxatives (senna, bisacodyl) are for short-term rescue, not daily maintenance. Always check the product label and your prescriber or pharmacist before starting a new regular laxative.
| Class | Examples | Best use | What labels & guidelines say |
|---|---|---|---|
| Osmotic (pulls water into the colon) | PEG 3350 (MiraLAX), lactulose, magnesium oxide, magnesium citrate | First-line OTC option for most GLP-1 constipation | PEG 3350 has strong AGA/ACG guideline support for adult chronic constipation. Works in 12–72 hours. The MiraLAX label says ask a doctor before use if you have kidney disease, nausea, vomiting, abdominal pain, sudden bowel-habit change >2 weeks, or IBS. Magnesium-based options: avoid with kidney disease and in older adults without supervision. |
| Bulk-forming fiber | Psyllium (Metamucil), methylcellulose (Citrucel) | Prevention. Adds bulk and softens stool. | Add gradually with plenty of water. Can worsen bloating if you don’t drink enough. AGA/ACG suggests fiber supplementation; NIDDK advises drinking plenty of liquids when increasing fiber. |
| Stool softener | Docusate (Colace) | Mild adjunct option | Helps if dryness is the main issue; modest effect on its own. Don’t add it to a growing laxative pile without checking with your pharmacist. |
| Stimulant (triggers colon contractions) | Senna (Senokot), bisacodyl (Dulcolax) | Short-term rescue when other steps haven’t worked | AGA/ACG suggests short-term or rescue use. NIDDK: if you can’t have a bowel movement without long-term stimulant laxative use, talk with your doctor about how to slowly stop. |
| Prescription | Linaclotide (Linzess), plecanatide (Trulance), prucalopride (Motegrity) | When OTC options aren’t enough | Different mechanisms — your prescriber chooses based on your situation. |
For an overview of GLP-1 safety more broadly, see Is GLP-1 Safe? The Honest 2026 Safety Guide.
Foods, Fiber, and Habits That Actually Help (and the Ones That Backfire)
Quick answer: Soluble fiber (oats, kiwi, chia, psyllium) softens stool without bulking it too aggressively for a slowed gut. Large high-fat meals often make the “stuck” feeling worse. Walking 10–15 minutes after meals stimulates a reflex that triggers colon contractions. Caffeine in moderation can help.
Foods most people on a GLP-1 tolerate well
- Kiwi — a 2023 RCT in adults with chronic constipation found two green kiwifruit per day improved stool frequency on par with a psyllium comparator
- Prunes or prune juice
- Oats and oat bran
- Chia seeds and ground flax (start with 1 tablespoon, work up)
- Berries
- Pears and apples with the skin
- Cooked vegetables (raw can be harder to digest with slowed motility)
- Beans and lentils, in small portions, if tolerated
Habits that move the needle
- A 10–15 minute walk after meals — triggers the gastrocolic reflex, which tells the colon to move
- A consistent bathroom time — NIDDK recommends trying to go 15–45 minutes after breakfast
- A footstool under your feet on the toilet — the squatting position straightens the angle of the colon
- Don’t ignore the urge. If your body says now, stop what you’re doing.
What backfires
- Dumping 30 grams of fiber into a backed-up system. Add slowly.
- Big high-fat meals (slowed gastric emptying + heavy fat = worse motility)
- Skipping fluids because you’re not thirsty. Set a reminder.
- “Cleanse” products — most are stimulant laxatives in disguise
Can I Take MiraLAX with Ozempic, Wegovy, Mounjaro, or Zepbound?
Quick answer: For most adults, yes — the FDA labels for semaglutide, tirzepatide, liraglutide, and dulaglutide don't list polyethylene glycol (PEG 3350, sold as MiraLAX) as a direct drug interaction, because PEG works locally in the gut and isn't significantly absorbed. The MiraLAX product label still says to ask a doctor or pharmacist before use if you take a prescription drug, have kidney disease, IBS, abdominal pain, nausea, vomiting, or a sudden bowel-habit change lasting more than two weeks — and not to use it longer than 7 days unless a doctor tells you to.
The interaction question
GLP-1 receptor agonists slow gastric emptying, and the FDA labels warn that the slowdown can affect how oral medications get absorbed. PEG 3350 isn't really “absorbed” in the typical sense — it's an osmotic laxative that stays in the gut, pulls water in, and gets passed in stool. That's why the GLP-1 labels we checked don't list it as a direct interaction.
The safety question
“No listed interaction” isn't the same as “right for everyone.” The MiraLAX OTC label specifically says to ask a doctor before use if you have kidney disease, nausea, vomiting, abdominal pain, IBS, or a sudden change in bowel habits lasting longer than two weeks. The recommended adult duration is up to 7 days unless a doctor tells you otherwise.
Does GLP-1 Constipation Mean I Have Gastroparesis?
Quick answer: No. Constipation alone doesn't prove gastroparesis. GLP-1 medications can slow gastric emptying — that's part of how they work — but most GLP-1 constipation is colon-side, not stomach-side. The FDA Zepbound label specifically does not recommend Zepbound in patients with severe gastroparesis, and the Rybelsus tablet label says the same. If constipation is paired with persistent vomiting, severe upper-belly fullness, inability to eat or hydrate, or worsening abdominal pain, that's a prescriber call now — not a “wait and see.”
| Constipation (colon-side) | Gastroparesis (stomach-side) |
|---|---|
| Stool moving too slowly through the colon | Stomach itself empties too slowly |
| Hard stool, straining, bloating, feeling blocked | Nausea, vomiting (sometimes hours after eating), early fullness |
| Fewer bowel movements | Bloating in the upper belly, sometimes weight loss |
| Usually manageable with home steps | Severe cases: reason NOT to start/continue certain GLP-1s |
You can have one without the other. You can have both. The labels above flag severe gastroparesis as a reason not to start (or continue) certain GLP-1s — that decision is your prescriber's, not a self-diagnosis.
When to Call Your Doctor — and When to Go to the ER
Quick answer: Call your prescriber if you've gone 5–7 days without a bowel movement despite the home plan, if every dose increase keeps triggering this, or if it's interfering with your life. Go to the ER for severe or worsening abdominal pain, persistent vomiting, a hard distended belly, inability to pass gas, fever with belly pain, blood or black/tarry stool, fainting, confusion, or severe dehydration — these can signal a bowel obstruction or fecal impaction.
| Symptom | What to do |
|---|---|
| Hard stools, going every 3–5 days, no severe pain, can pass gas | Run the home plan |
| Going 5–7 days + bloating, home plan not working | Call your prescriber within 24–48 hours |
| Severe or worsening abdominal pain | ER now |
| Persistent vomiting, especially can’t keep fluids down | ER now |
| Hard, distended (visibly swollen) belly | ER now |
| Cannot pass any gas at all | ER now |
| Fever + abdominal pain | ER now |
| Blood in stool, black/tarry stool | ER or urgent care |
| Fainting, confusion, severe dehydration | ER now |
| Repeated impaction episodes (more than once) | Call prescriber to re-evaluate medication or dose |
The FDA prescribing information for Zepbound, Mounjaro, Saxenda, and Trulicity all include post-marketing reports of ileus (a stalled intestine), intestinal obstruction, and severe constipation including fecal impaction. Post-marketing means these were reported after the drug was approved, in voluntary reports. But they're listed because they happened, and they're serious enough that the symptoms above should never be managed by adding more laxatives at home.
Should You Stop Your GLP-1 Because of Constipation?
Quick answer: Not on your own. In adult Wegovy 2.4 mg trials, 4.3% of patients permanently stopped due to GI adverse reactions — and the Wegovy label lists nausea, vomiting, and diarrhea (not constipation) as the most common adverse reactions leading to discontinuation. The usual prescriber options for tough constipation are slowing the next dose escalation, staying longer at the current dose, stepping back to the prior dose, treating the constipation more deliberately, or switching medications.
Option 1: Slow the titration
If you’re struggling, your prescriber may keep you on the current dose longer to let your gut catch up before the next increase.
Option 2: Hold or step back the dose
If you just stepped up and the constipation flared, going back to the prior dose for a stretch often resolves it. Then you try again.
Option 3: Switch molecules
Semaglutide and tirzepatide cause similar GI effects but not identical ones. Some people tolerate one better than the other.
Option 4: Stop entirely
Reserved for cases of severe ileus, recurrent fecal impaction, or another serious GI event. This is your prescriber’s call, not yours alone.
Special Situations: When the Standard Plan Isn't Enough
Quick answer: If you have IBS-C, gastroparesis, prior bowel obstruction, kidney disease, take opioids or iron supplements, or are pregnant or breastfeeding, the standard plan needs adjusting. Build a plan with your prescriber — not from a generic article.
- If you have IBS-C or chronic constipation already
- GLP-1 is layering on top of an existing problem. Expect more constipation than the FDA-label rates suggest, plan a prevention routine before starting, and bring up prescription options (linaclotide, plecanatide) with your prescriber if you’re already using them.
- If you have a history of gastroparesis or bowel obstruction
- This is the highest-stakes group. The FDA Zepbound label is explicit: not recommended in severe gastroparesis. The Rybelsus tablet label says the same. If you’ve had an obstruction or significant gastroparesis, this is a conversation with your prescriber before you start, not after you’re stuck.
- If you have kidney disease
- Magnesium-based laxatives (magnesium oxide, magnesium citrate) are filtered by the kidneys, and impaired kidneys can let magnesium build up to dangerous levels — avoid them without medical supervision. PEG (MiraLAX) may be an option, but the MiraLAX label says not to use it with kidney disease except under a doctor’s advice.
- If you take opioids, iron supplements, or anticholinergic medications
- All three slow the gut on their own. Stacking them with a GLP-1 amplifies the constipation. Tell your prescriber what you’re taking — there may be alternatives or you may need a more aggressive prevention plan.
- If you’re a teenager on Wegovy
- In the FDA pediatric trial (ages 12+), 62% of Wegovy-treated patients reported any GI adverse event vs. 42% on placebo. Constipation specifically was 6% on Wegovy vs. 2% on placebo. Build a routine early.
- If you’re pregnant or thinking you could be
- The Wegovy label says it may cause fetal harm and instructs to discontinue Wegovy when pregnancy is recognized for weight reduction or cardiovascular risk reduction. If you became pregnant while on a GLP-1, this is an immediate prescriber conversation, not a constipation question.
- If you’re an older adult
- Slower baseline gut, more medications, higher risk of dehydration. The same plan applies but with more conservative steps and earlier prescriber check-ins.
Compounded vs Brand-Name GLP-1s — Does Constipation Differ?
Quick answer: The active molecule and dose drive constipation, not the brand. The same molecule at the same dose should produce a similar class of GI effects. What's different is the safety picture around the product itself: the FDA states that compounded GLP-1 drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. The FDA has reported dosing errors, hospitalizations, and “semaglutide salt” formulations that are technically different active ingredients from approved drugs.
| What's true at the receptor level | What's different about the product |
|---|---|
| Semaglutide is semaglutide; the molecule binds the same GLP-1 receptors regardless of where it was made. | Compounded GLP-1 products are not FDA-approved. They’re not reviewed for safety, effectiveness, or quality before being sold. |
| Same molecule + same dose = same general class of GI side effects, including constipation. | The FDA has reported dosing errors and hospitalizations tied to compounded GLP-1 products. |
| Slower titration eases GI side effects on either compounded or brand-name. | Some compounded products use “semaglutide salt” forms that are technically different active ingredients than the approved drug. |
| Walking, fluids, fiber, PEG — all the same. | Concentration, vial markings, and titration schedules vary by pharmacy; there’s no single label to check. |
How to Track This and What to Tell Your Prescriber
Quick answer: Track your medication and dose, your last dose date, your last bowel movement, stool texture, ability to pass gas, pain level, and what you've tried. A clear, factual message helps your prescriber decide between routine constipation, a dose-tolerance issue, or a red-flag situation faster.
When constipation reaches the “call the prescriber” line, the worst thing you can do is text “I'm constipated, what do I do?” and wait. The best thing you can do is send a complete picture in one message.
Copy-paste template
Hi Dr. [Name]. I'm taking [drug name] at [current dose]. My last injection was [date]. My last dose increase was on [date]. My last full bowel movement was [date/time]. The stool was [soft / hard / pellets / dry]. I [can / cannot] pass gas. My pain level is [0\u201310] in the [location]. I [am / am not] vomiting. My belly is [not bloated / mildly bloated / very bloated and tight]. So far I've tried: [list \u2014 fluids, fiber, MiraLAX, magnesium, senna, etc.]. I have the following medical conditions or take the following other medications: [list]. Can we discuss whether I should continue at this dose, delay the next increase, adjust medication, or use a stronger bowel regimen?
Frequently Asked Questions
- Is GLP-1 constipation common?
- Yes. Per current FDA prescribing information, constipation is reported in about 24% of adults on Wegovy 2.4 mg, 20% on Wegovy 7.2 mg, 19% on Saxenda, 11–17% on Zepbound, 6–7% on Mounjaro, 5–6% on Rybelsus, and 3–5% on Ozempic. Rates vary by drug, dose, indication, and trial — the weight-management labels generally report higher percentages than the diabetes-label tables.
- How long does GLP-1 constipation last?
- Most cases show up early in treatment — onset typically in the first 16 weeks, especially the first 28 days. The 2022 multidisciplinary expert consensus reported a median duration of about 47 days in people with obesity on GLP-1 therapy. Each dose increase can trigger a fresh 1–3 week flare. Persistent severe symptoms past several months on a stable dose should trigger a prescriber review.
- What is the best laxative for GLP-1 constipation?
- Polyethylene glycol (PEG 3350, sold as MiraLAX) has the strongest guideline support among OTC options for adult chronic constipation, and the FDA GLP-1 labels we checked do not list it as a direct interaction. It’s an osmotic laxative that pulls water into the colon. Confirm with your pharmacist or prescriber for your specific situation — especially with kidney disease, IBS, pregnancy, or other prescription medications.
- Can I take MiraLAX with Ozempic, Wegovy, Mounjaro, or Zepbound?
- For most adults, yes. PEG 3350 is not significantly absorbed, so it does not appear in GLP-1 label interaction lists. The MiraLAX product label still says to ask a doctor before use if you have kidney disease, nausea, vomiting, abdominal pain, IBS, or a sudden bowel-habit change lasting more than two weeks — and not to use it longer than 7 days unless a doctor tells you to.
- Does GLP-1 constipation mean I have gastroparesis?
- No. Constipation alone does not prove gastroparesis. The FDA Zepbound label and the Rybelsus tablet label both say not to use those products in patients with severe gastroparesis. If constipation is paired with persistent vomiting, severe upper-belly fullness, or worsening abdominal pain, contact your prescriber promptly.
- Should I stop my GLP-1 because of constipation?
- Usually not on your own. About 4.3% of adult Wegovy patients permanently stopped due to any GI side effect, and the Wegovy label lists nausea, vomiting, and diarrhea as the most common adverse reactions leading to discontinuation. The usual alternatives are slowing dose escalation, holding the current dose, stepping back to the prior dose, or switching medications — discuss with your prescriber before making changes.
- When should I worry about constipation on a GLP-1?
- Call your prescriber if you have gone 5–7 days without a bowel movement despite the home plan, or if every dose increase keeps triggering this. Go to the ER for severe or worsening abdominal pain, persistent vomiting, a hard distended belly, inability to pass gas, fever, blood or black/tarry stool, fainting, confusion, or severe dehydration — these can signal a bowel obstruction or fecal impaction.
- Is constipation a sign my GLP-1 is working?
- No. The same mechanism that helps you feel full longer (slowed gastric emptying) can also cause constipation, but constipation is not a measure of how well the drug is working. People who don’t get constipated still get the appetite-suppression and glucose-lowering effects.
- What is the best fiber for GLP-1 constipation?
- Soluble fiber from psyllium husk (Metamucil) is most often recommended because it softens stool without bulking it too aggressively for a slowed gut. Start with one teaspoon daily and increase gradually with plenty of water. Methylcellulose (Citrucel) is a similar option that may cause less gas.
- Does Mounjaro cause more constipation than Ozempic?
- At diabetes doses, the FDA-label rates are similar — Mounjaro 6–7%, Ozempic 3–5%. At weight-management doses, Zepbound (11–17%) and Wegovy (24% at 2.4 mg, 20% at 7.2 mg) both report meaningfully higher rates than their diabetes counterparts. These aren’t head-to-head trials, so the table is best read as “what each label reports,” not as a ranking.
- How do you poop on a GLP-1?
- Drink fluids steadily, walk 10–15 minutes after meals, add psyllium fiber gradually with extra water, take polyethylene glycol (MiraLAX) per its label if you need OTC help, and use a footstool to put yourself in a squatting position on the toilet. If you’ve gone 5+ days without a bowel movement and the home plan isn’t working, call your prescriber.
- Can GLP-1 cause bowel obstruction or fecal impaction?
- Rarely, yes. The FDA prescribing information for Zepbound, Mounjaro, Saxenda, and Trulicity all include post-marketing reports of ileus, intestinal obstruction, and severe constipation including fecal impaction. These reports are voluntary and don’t establish exact frequency or prove cause, but they’re serious enough that severe abdominal pain, persistent vomiting, no gas passing, or a hard distended belly should send you to the ER.
- What if I haven’t pooped in a week on Ozempic, Wegovy, Mounjaro, or Zepbound?
- Seven-plus days without a bowel movement warrants a call to your prescriber, especially with bloating, pain, or vomiting. Severe abdominal pain, persistent vomiting, fever, blood or black/tarry stool, or inability to pass gas means ER, not phone call. Don’t keep stacking laxatives at home past day 7 without medical input.
What We Actually Verified for This Page
We don't ask you to take our word for it. Here's exactly what we checked.
Verified:
- Every constipation rate in the comparison table was pulled from the current FDA prescribing information for that drug on DailyMed (links in the sources section below).
- Every placebo rate in the same table was pulled from the matching trial’s adverse-reaction table on the same DailyMed label.
- The 47-day median duration and “first 16 weeks / first 28 days” timing comes from Gorgojo-Martínez et al. (2022), published in the Journal of Clinical Medicine (PMC9821052).
- The wireless motility-capsule data (80% delayed gastric emptying, 44% delayed whole-gut transit) comes from a 2025 retrospective single-center case series of 10 patients in ACG Case Reports Journal (PubMed 40761333).
- The post-marketing reports of ileus, intestinal obstruction, severe constipation, and fecal impaction are listed in the relevant FDA prescribing-information sections for Zepbound, Mounjaro, Saxenda, and Trulicity.
- The AGA/ACG laxative guidance comes from the joint guideline on pharmacological management of chronic idiopathic constipation.
- The MiraLAX label warnings come from the FDA-cleared OTC product label on DailyMed.
- NIDDK constipation guidance comes from NIDDK constipation pages.
- Mayo Clinic red-flag criteria come from the Mayo Clinic constipation symptoms-and-causes page.
- The 2023 kiwifruit trial: Chey WD et al., comparing two green kiwifruit per day to psyllium in adults with chronic constipation and IBS-C, published in the American Journal of Gastroenterology.
- FDA compounded GLP-1 safety statements come from the FDA’s “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” page.
Not verified by us (and you shouldn't take it from any single page on the internet):
- Your individual response to any specific medication or laxative — that depends on your medical history, other medications, kidney function, age, and dozens of other factors only your prescriber and pharmacist can weigh.
- Whether a specific OTC product is safe for you — same answer.
- The exact frequency of post-marketing events like obstruction or impaction. Post-marketing reports are voluntary and can’t establish a true rate.
Refresh cadence: quarterly. We re-check every FDA label, the consensus paper, AGA/ACG guidance, NIDDK pages, FDA compounded-GLP-1 safety updates, and Mayo Clinic guidance every three months and update anything the change affects.
Sources
- DailyMed: Wegovy (semaglutide injection)
- DailyMed: Ozempic (semaglutide injection)
- DailyMed: Rybelsus (semaglutide tablets)
- DailyMed: Mounjaro (tirzepatide)
- DailyMed: Zepbound (tirzepatide)
- DailyMed: Saxenda (liraglutide)
- DailyMed: Victoza (liraglutide)
- DailyMed: Trulicity (dulaglutide)
- DailyMed: MiraLAX OTC label
- Gorgojo-Martínez et al. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists. J Clin Med. PMC9821052
- Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule. ACG Case Reports Journal, 2025. PubMed 40761333
- AGA/ACG: Pharmacological Management of Chronic Idiopathic Constipation
- NIDDK: Treatment for Constipation
- Mayo Clinic: Constipation — Symptoms and Causes
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Chey WD et al. Kiwifruit Improves Stool Frequency and Symptoms in Patients With Chronic Constipation and IBS-C. Am J Gastroenterol, 2023.
A Note on Who Wrote This and Why
We're TheRxIndex's editorial team. We build pages on GLP-1 medications because most search results for these drugs are either thin sales-funnel content or cautious medical-encyclopedia entries that don't help you decide what to do tonight. We're not your prescribers, and this page isn't a substitute for one. It's the page we wish existed when we started verifying the labels and side-effect guidance for ourselves.
If your prescriber tells you something different from what's here, follow your prescriber. They know your full medical picture; we don't.